Literature DB >> 17508040

Natural compounds: evidence for a protective role in eye disease.

Robert Ritch1.   

Abstract

Glaucoma often progresses despite lowering of intraocular pressure (IOP) to acceptable or normal levels; it can also develop at normal or even low IOP on the basis of non-IOP-dependent risk factors. Therefore, a need exists for therapies limiting damage due to glaucoma that are independent of therapies that simply lower IOP. The aim of neuroprotection in glaucoma is to slow progression by blocking the mechanisms that lead to apoptosis. Many compounds have been described as neuroprotective, but the lack of availability of specific neuroprotectant compounds and the lack of clinical trials examining the benefits of neuroprotective agents for glaucoma limit their current therapeutic use. There are, however, many available natural compounds that offer the possibility of neuroprotective activity. This review summarizes the potential benefits of natural compounds in the treatment of eye disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508040     DOI: 10.3129/can j ophthalmol.i07-044

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  15 in total

1.  N-acetylcysteine protects against hypoxia mimetic-induced autophagy by targeting the HIF-1α pathway in retinal ganglion cells.

Authors:  Lan Yang; Panpan Tan; Wei Zhou; Xu Zhu; Yongyao Cui; Liang Zhu; Xuemei Feng; Hong Qi; Jun Zheng; Ping Gu; Xianqun Fan; Hongzhuan Chen
Journal:  Cell Mol Neurobiol       Date:  2012-05-23       Impact factor: 5.046

2.  Sulbutiamine counteracts trophic factor deprivation induced apoptotic cell death in transformed retinal ganglion cells.

Authors:  Kui Dong Kang; Aman Shah Abdul Majid; Kyung-A Kim; Kyungsu Kang; Hong Ryul Ahn; Chu Won Nho; Sang Hoon Jung
Journal:  Neurochem Res       Date:  2010-08-31       Impact factor: 3.996

3.  A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients.

Authors:  R Jothi; A M Ismail; R Senthamarai; Siddhartha Pal
Journal:  Indian J Pharmacol       Date:  2010-12       Impact factor: 1.200

4.  Metabolomics Reveals Differences in Aqueous Humor Composition in Patients With and Without Pseudoexfoliation Syndrome.

Authors:  Diana Anna Dmuchowska; Karolina Pietrowska; Pawel Krasnicki; Tomasz Kowalczyk; Magdalena Misiura; Emil Tomasz Grochowski; Zofia Mariak; Adam Kretowski; Michal Ciborowski
Journal:  Front Mol Biosci       Date:  2021-05-14

5.  Naturalistic Evaluation of Prescription Pattern in Glaucoma Clinic of a Tertiary Care Hospital: A Developing Country's Perspective.

Authors:  Niraj Niraj; Nusrat Shafiq; Sushmita Kaushik; Chakrant Mothsara; Gaurav Garg; Samir Malhotra
Journal:  J Pharm Bioallied Sci       Date:  2020-12-16

Review 6.  Neuroprotection in glaucoma.

Authors:  Sushil K Vasudevan; Viney Gupta; Jonathan G Crowston
Journal:  Indian J Ophthalmol       Date:  2011-01       Impact factor: 1.848

7.  Multifocal electroretinogram and Optical Coherence tomography spectral-domain in arc welding macular injury: a case report.

Authors:  Mauro Cellini; Roberto Gattegna; Pier Giorgio Toschi; Ernesto Strobbe; Emilio C Campos
Journal:  BMC Ophthalmol       Date:  2011-12-30       Impact factor: 2.209

Review 8.  Helicobacter pylori infection and eye diseases: a systematic review.

Authors:  Sergio Claudio Saccà; Aldo Vagge; Alessandra Pulliero; Alberto Izzotti
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

9.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

10.  Botanical compounds: effects on major eye diseases.

Authors:  Tuan-Phat Huynh; Shivani N Mann; Nawajes A Mandal
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-17       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.